Skip to content
Loading…
Dr Reddy's CEO Erez Israeli expects a healthy performance in the second half of FY2026-27 once the company resolves the semaglutide issue. Israeli believes the generics market for semaglutide in will be ultra-competitive, with more than 20 companies trying to gain market share.…
To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.